Evidence map›Paper›PMID 36340445›Full record

ArticleCancer diagnosis & prognosis

Octogenarians With Anaplastic Lymphoma Kinase-rearranged Non-small-cell Lung Cancer: A Case Series.

Sou Hattori, Eiji Ojima, Shinichiro Okauchi, Yuika Sasatani, Toshihiro Shiozawa, Hiroaki Satoh, Nobuyuki Hizawa

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 76% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Sou HattoriDivision of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Japan.
Eiji OjimaDivision of Cardiology, Mito Medical Center, University of Tsukuba, Mito, Japan.
Shinichiro OkauchiDivision of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Japan.
Yuika SasataniDivision of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Japan.
Toshihiro ShiozawaDivision of Respiratory Medicine, Faculty of Clinical Medicine, University of Tsukuba, Tsukuba, Japan.
Hiroaki SatohDivision of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Japan.
Nobuyuki HizawaDivision of Respiratory Medicine, Faculty of Clinical Medicine, University of Tsukuba, Tsukuba, Japan.
National Hospital Organization Mito Medical Center · JPUniversity of Tsukuba · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimAnaplastic lymphoma kinase (ALK) rearrangements define a distinct group of patients with non-small-cell lung cancer (NSCLC), mainly represented by never-smoking young individuals. However, we also encounter elderly patients with ALK-rearranged NSCLC over the age of 80 years. We report herein three cases of these patients that we have experienced. CASE REPORT: Three patients with ALK-rearranged NSCLC aged 80 years or older received therapy with the ALK-tyrosine kinase, alectinib. Of them, one was male and two had a history of smoking. Comorbidities, especially heart diseases, were prominent. Long-term survival was achieved with alectinib treatment in two patients.

conclusionALK-rearranged mutations should be evaluated even in octogenarians with NSCLC, regardless of sex and smoking history. Even if they have comorbid diseases, long-term control might be achieved with alectinib therapy in cooperation with physicians other than chest physicians and medical oncologists.

Indexed as

Anaplastic lymphoma kinaseelderlylong-term survivorlung adenocarcinomaoctogenarian

Identifiers

PMID36340445
PMCPMC9628154
OpenAlexW4308551119

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.